These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 11834950

  • 1. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.
    Falloon J, Ait-Khaled M, Thomas DA, Brosgart CL, Eron JJ, Feinberg J, Flanigan TP, Hammer SM, Kraus PW, Murphy R, Torres R, Masur H, CNA2007 Study Team.
    AIDS; 2002 Feb 15; 16(3):387-96. PubMed ID: 11834950
    [Abstract] [Full Text] [Related]

  • 2. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M, Rakik A, Griffin P, Stone C, Richards N, Thomas D, Falloon J, Tisdale M, CNA2007 International Study Team.
    Antivir Ther; 2003 Apr 15; 8(2):111-20. PubMed ID: 12741623
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.
    de Truchis P, Force G, Welker Y, Mechali D, Pulik M, Chemlal K, Rouveix E, Devidas A, Praindhui D, Mamet JP, CNAF3008 Group.
    J Acquir Immune Defic Syndr; 2002 Oct 01; 31(2):178-82. PubMed ID: 12394796
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.
    Falloon J, Piscitelli S, Vogel S, Sadler B, Mitsuya H, Kavlick MF, Yoshimura K, Rogers M, LaFon S, Manion DJ, Lane HC, Masur H.
    Clin Infect Dis; 2000 Feb 01; 30(2):313-8. PubMed ID: 10671334
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
    Schooley RT, Clumeck N, Haubrich R, Thompson M, Danner SA, van Der Ende ME, Sereni D, Antunes F, Blake D, Myers RE, Tisdale M, Millard J, Mustafa N, Nacci P.
    Antivir Ther; 2001 Jun 01; 6(2):89-96. PubMed ID: 11491421
    [Abstract] [Full Text] [Related]

  • 9. Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
    Ochoa de Echagüen A, Arnedo M, Xercavins M, Martinez E, Rosón B, Ribera E, Domingo P, González A, Riera M, Llibre JM, Gatell JM, Dalmau D, Nevirapine, Efavirenz and Abacavir (NEFA) Resistance Substudy Team.
    AIDS; 2005 Sep 02; 19(13):1385-91. PubMed ID: 16103769
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C, Race E, Castiel P, Belec L, Peytavin G, Si-Mohamed A, Gonzalez-Canali G, Weiss L, Clavel F, Kazatchkine MD.
    AIDS; 1999 Jul 30; 13(11):F71-7. PubMed ID: 10449277
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P, Lang J, DeJesus E, Berger DS, Dretler R, Rodriguez A, Ward DJ, Lim ML, Liao Q, Reddy S, Clair MS, Vila T, Shaefer MS.
    HIV Clin Trials; 2006 Jul 30; 7(5):229-36. PubMed ID: 17162316
    [Abstract] [Full Text] [Related]

  • 13. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E, Bini T, Adorni F, Capetti A, Rizzardini G, Faggion I, Mussini C, Sollima S, Melzi S, Bongiovanni M, Tordato F, Cicconi P, Castelnuovo B, Rusconi S, d'Arminio Monforte A.
    Antivir Ther; 2003 Feb 30; 8(1):27-35. PubMed ID: 12713061
    [Abstract] [Full Text] [Related]

  • 14. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.
    Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Ait-Khaled M, Purdon S.
    AIDS; 2000 May 05; 14(7):781-9. PubMed ID: 10839585
    [Abstract] [Full Text] [Related]

  • 15. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs.
    Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, Albrecht MA, ACTG 364 Study Team.
    AIDS; 2003 Apr 11; 17(6):821-30. PubMed ID: 12660529
    [Abstract] [Full Text] [Related]

  • 16. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
    Bickel M, Rickerts V, Stephan C, Jacobi V, Rottmann C, Dauer B, Carlebach A, Thalhammer A, Miller V, Staszweski S.
    HIV Med; 2005 May 11; 6(3):179-84. PubMed ID: 15876284
    [Abstract] [Full Text] [Related]

  • 17. Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.
    Swindells S, Cohen CJ, Berger DS, Tashima KT, Liao Q, Pobiner BF, Snidow JW, Pakes GE, Hernandez JE, NZTA4008 Study Team.
    BMC Infect Dis; 2005 Apr 08; 5():23. PubMed ID: 15819974
    [Abstract] [Full Text] [Related]

  • 18. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjaer J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L, EuroSIDA Study Group.
    Antivir Ther; 2004 Oct 08; 9(5):787-800. PubMed ID: 15535417
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.